2-NBDG fluorescence imaging of hypermetabolic circulating tumor cells in mouse xenograft model of breast cancer.
2-NBDG fluorescence imaging of hypermetabolic circulating tumor cells in mouse xenograft model of breast cancer.
复制标题
DOI：
10.1007/s10895-012-1136-z
复制
发表时间：
2013-01
影响因子：
2.7
通讯作者：
Peng F
中科院分区：
文献类型：
--
作者：
Cai H;Peng F
确定2-[N-（7-硝基苯-2-氧杂-1，3-二氮唑-4-基）氨基]-2-脱氧-D-葡萄糖（2-NBDG）作为荧光成像检测高代谢循环肿瘤细胞（CTC）的示踪剂的用途。将人乳腺癌细胞植入无胸腺小鼠的乳腺脂肪垫中，以建立原位人乳腺癌异种移植物作为循环乳腺癌细胞的小鼠模型。对注射2-脱氧葡萄糖酮750（2-DG 750）的荷瘤小鼠进行近红外荧光成像，以评估异种移植肿瘤的葡萄糖代谢。在与荧光2-NBDG孵育后，通过磁分离收集从荷瘤小鼠收集的血液样品中的循环乳腺癌细胞，然后对循环乳腺癌细胞的2-NBDG摄取进行荧光成像，并将高代谢循环乳腺癌细胞的数量与收集血液样品时的肿瘤大小进行关联。在注射2-DG 750的荷瘤小鼠的近红外荧光成像上观察源自MDA-MB-231、BT474或SKBR-3细胞的人乳腺癌异种移植肿瘤。在荷瘤小鼠的血液样品中检测到具有增加的荧光2-NBDG摄取的高代谢循环乳腺癌细胞，并通过荧光成像进行可视化，但在正常对照小鼠的血液样品中未检测到。高代谢循环乳腺癌细胞的数量沿着异种移植肿瘤的生长而增加，在携带MDA-MB 231异种移植物的小鼠中检测到的高代谢循环乳腺癌细胞的数量大于携带BT 474或SKBR-3异种移植物肿瘤的小鼠中检测到的高代谢循环乳腺癌细胞的数量。通过荧光成像在携带人乳腺癌异种移植肿瘤的小鼠中检测到具有增加的荧光2-NBDG摄取的循环乳腺癌细胞，表明2-NBDG作为高代谢循环乳腺癌细胞的荧光成像的示踪剂的临床用途。
To determine use of 2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG) as a tracer for detection of hypermetabolic circulating tumor cells (CTC) by fluorescence imaging. Human breast cancer cells were implanted in the mammary gland fat pad of athymic mice to establish orthotopic human breast cancer xenografts as a mouse model of circulating breast cancer cells. Near-infrared fluorescence imaging of the tumor-bearing mice injected with 2-DeoxyGlucosone 750 (2-DG 750) was conducted to assess glucose metabolism of xenograft tumors. Following incubation with fluorescent 2-NBDG, circulating breast cancer cells in the blood samples collected from the tumor-bearing mice were collected by magnetic separation, followed by fluorescence imaging for 2-NBDG uptake by circulating breast cancer cells, and correlation of the number of hypermetabolic circulating breast cancer cells with tumor size at the time when the blood samples were collected. Human breast cancer xenograft tumors derived from MDA-MB-231, BT474, or SKBR-3 cells were visualized on near-infrared fluorescence imaging of the tumor-bearing mice injected with 2-DG 750. Hypermetabolic circulating breast cancer cells with increased uptake of fluorescent 2-NBDG were detected in the blood samples from tumor-bearing mice and visualized by fluorescence imaging, but not in the blood samples from normal control mice. The number of hypermetabolic circulating breast cancer cells increased along with growth of xenograft tumors, with the number of hypermetabolic circulating breast cancer cells detected in the mice bearing MDA-MB231 xenografts larger than those in the mice bearing BT474 or SKBR-3 xenograft tumors. Circulating breast cancer cells with increased uptake of fluorescent 2-NBDG were detected in mice bearing human breast cancer xenograft tumors by fluorescence imaging, suggesting clinical use of 2-NBDG as a tracer for fluorescence imaging of hypermetabolic circulating breast cancer cells.